- June 22, 2021
Date: June 22, 2021
Time: 10:00-5:00 p.m. ET
Location: Virtual Meeting (Zoom Webinar)
Meeting Registration Site: https://cvent.me/eXw9lG
Osteoarthritis (OA) represents a significant public health issue associated with morbidity and long-term disability in many people. Current therapies of OA focus on short-term outcomes such as alleviating pain; however, treatments that inhibit structural damage or target the underlying pathophysiology associated with OA remain elusive and represent an unmet medical need.
The FDA and the Arthritis Foundation (AF) have joined forces for this workshop to leverage their combined strengths to bring together subject matter experts in the field of diagnosis, research, development, and treatment of OA.
Goals and Objectives
The goal of this workshop is to provide a forum for continued open discussion between leading osteoarthritis experts in academia, industry, the non-profit sector, and government, with the ultimate goal of expediting the development of safe and effective treatments intended to provide long-term benefit in OA. Initial objectives include:
- Identify promising innovations that could facilitate successful clinical trials in OA.
- Identify study designs and clinically meaningful trial endpoints that demonstrate long-term clinical benefit to patients with OA.
- Discuss the role of biomarkers in drug development in OA.
Who Should Attend
This public workshop is intended for interested parties regarding ongoing efforts in the area of OA.
The primary audience includes leading academic experts, non-profit organizations, scientists, clinicians from regulatory, academic, industrial and other healthcare sectors, scientists involved in research and drug development in those same industries, regulatory scientists, experts and leaders from industry, academia, regulatory government agencies in the US and abroad, patient representatives, and healthcare providers who are interested in the treatment of OA.
- Final Agenda (PDF - 59KB)
If to AF: Jason Kim, email@example.com
If to FDA: Sadaf Nabavian, firstname.lastname@example.org
|Final Agenda - FDA-Arthritis Foundation Osteoarthritis Drug Development Workshop||pdf (58.00 KB)|